All the news Showing 10 of 47 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C Keith Alcorn / 28 April 2015 People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious co-morbidity such as HIV infection, chronic kidney disease ... Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... Hepatitis delta virus co-infection increases risk of poor liver-related outcomes for people living with HIV Michael Carter / 07 April 2014 Co-infection with hepatitis delta virus (HDV) is a major risk factor for hepatic decompensation and liver-related death in people living with HIV, Spanish investigators report in the online edition of Clinical Infectious Diseases. Over ... New-onset diabetes accelerates the pace of liver disease in people with chronic HBV Michael Carter / 02 October 2013 New-onset diabetes is associated with the development of liver cirrhosis and decompensated cirrhosis in people with chronic hepatitis B virus (HBV) infection, according to the results of a study published in the online ... Combining tenofovir with FTC or 3TC boosts chances of HBV suppression for people co-infected with HIV Michael Carter / 19 February 2013 A study involving people co-infected with HIV and hepatitis B virus (HBV) shows that antiretroviral therapy that combines tenofovir with FTC or 3TC has the best chance of suppressing HBV replication to undetectable ... Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis Michael Carter / 18 December 2012 Co-infection with HIV and viral hepatitis is associated with a more aggressive disease course for liver cancer, according to research conducted in London and presented to the recent EASL Monothematic Conference: HIV and ... Nucleoside analogues reduce hepatitis B liver cancer risk Liz Highleyman / 29 November 2012 Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection surgery, according to data presented ... Dramatic increase in incidence of liver cancer in HIV-positive people with viral hepatitis Michael Carter / 29 October 2012 Incidence of liver cancer among people with HIV has increased dramatically over the past decade, Spanish investigators report in the online edition of Clinical Infectious Diseases. All the cases involved individuals with ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive